Review Article

Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis

Lei Zhang, Hong Wang, Jizheng Tian, Lili Sui, and Xiaoyan Chen

Department of Oncology, The Hospital of Shunyi District of Beijing, Beijing 101300, China

Correspondence should be addressed to Xiaoyan Chen; xiaoyanchen_542@126.com

Received 11 March 2022; Revised 17 May 2022; Accepted 28 May 2022; Published 5 July 2022

Academic Editor: Bing Niu

Copyright © 2022 Lei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Statins are suggested to improve cancer survival by possible anti-inflammatory effect. However, it remains unclear if concomitant use of statins could improve the efficacy of immune checkpoint inhibitors (ICIs) in patients with non-small-cell lung cancer (NSCLC). Accordingly, a meta-analysis was performed to systematically evaluate the effect of concomitant statins in NSCLC patients receiving ICIs. Relevant studies were obtained by literature search in PubMed, Embase, and Web of Science databases. A conservative random-effect model was used to combine the results. Eight cohorts including 2382 patients were included. The programmed death-1/ligand-1 inhibitors were used in seven studies; while the cytotoxic T-lymphocyte-associated protein 4 inhibitors were used in the other study. It was shown that concomitant use of statin did not significantly affect the progression-free survival (PFS, hazard ratio (HR): 0.86, 95% confidence interval (CI): 0.70 to 1.07, \( P = 0.17; I^2 = 62\% \)) or overall survival (OS, HR: 0.86, 95% CI: 0.74 to 1.01, \( P = 0.07; I^2 = 29\% \)) of NSCLC patients receiving ICIs. Subgroup analyses showed consistent results in studies with univariate or multivariate analytic models (\( P \) for subgroup analysis = 0.97 and 0.38 for the outcome of PFS and OS, respectively). In conclusion, concomitant use of statin seemed to have no significant influence on the survival of patients with NSCLC who were treated with ICIs.

1. Introduction

Immune checkpoint inhibitors (ICIs) are a group of novel anticancer agents which showed substantial therapeutic efficacy in patients with various solid cancers, including patients with non-small-cell lung cancer (NSCLC) [1–3]. Current ICIs primarily include the programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors and cytotoxic T-lymphocyte associated protein 4 (CTLA4) inhibitors, which were shown to confer superior efficacy and less side effects as compared to conventional chemotherapy in patients with NSCLC [4, 5]. For patients with resectable NSCLC, a recent meta-analysis showed that neoadjuvant immunotherapy was feasible and safe, with major pathological response achieved in 52% of the patients and a low 30-day mortality of 0.6% [6]. The other systematic review and meta-analysis with 66 real-world studies confirmed the benefit of ICIs on survival in patients with pretreated and advanced NSCLC [7]. In view of the promising results of clinical trials, it could be anticipated that the use of ICIs in cancer will be increasing in patients with NSCLC [8]. However, previous studies also showed that therapeutic responses to ICIs varied among patients with cancer [9, 10]. For example, it has been shown that differences in age group, smoking history, metastasis status/site, and region may modify the potency of PD-1 inhibitors for the treatment of NSCLC [11]. Besides, concurrent medications have also been suggested to affect the therapeutic efficacy of ICIs in patients with various cancers [12]. Therefore, identification of clinical factors which may affect the efficacy of ICIs in patients with NSCLC is important in real-world clinical practice to maximize the possible benefit of ICIs [13].

The 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors, also named as statins, are well-applied
lipid-lowering medications [14]. Statins are commonly prescribed for patients with atherosclerosis and cardiovascular diseases, and about one-fifth of cancer patients receiving ICIs are also on statins [15]. Accumulating evidence shows that statins may also exert anticancer efficacy via multiple pharmacological mechanisms such as anti-proliferation, anti-inflammation, proapoptosis, and anti-invasion [16, 17]. Accordingly, previous meta-analyses of observational studies have shown that statin use may favorably affect the survival of patients with lung cancer [18, 19]. However, none of the included studies in these meta-analyses included NSCLC patients treated with ICIs. Emerging evidence shows that statins also confer immunomodulation efficacy, which may synergistically enhance the anticancer efficacy of ICIs [20, 21]. However, a recent preclinical study showed that statins may decrease the expression of PD-L1 in multiple cancer cell lines, including lung cancer, which raised the concern that concomitant statin use may interfere with the anticancer efficacy of ICIs [22]. Accordingly, results of recent observational studies evaluating the influence of concomitant statin use on survival of NSCLC patients treated with ICIs were not consistent [15, 23–28]. Some studies suggested that concomitant statin use may improve the survival of these patients [23, 25, 28], while others did not show a significant influence [15, 24, 26, 27, 29]. Therefore, this meta-analysis was conducted to systematically evaluate the effect of concomitant statins on the therapeutic efficacy of ICIs in patients with NSCLC.

2. Materials and Methods

The Meta-Analysis of Observational Studies in Epidemiology (MOOSE) [30] statement was followed in conceiving, conducting, and reporting the study, and the methodology of the meta-analysis was in accordance with the recommendations of the Cochrane’s Handbook [31] guideline. This meta-analysis was registered at INPLASY (International Platform of Registered Systematic Review and Meta-Analysis Protocols) with the registration number of INPLASY202250110.

2.1. Literature Retrieval. Studies fitting to the aim of the meta-analysis were retrieved by electronic database search of PubMed, EMBASE, and Web of Science from the inception of the databases to May 11, 2022. A combined search term was used, which is shown in Supplementary Materials. Filters of human studies, full-length articles, and publication in English were applied in the database search. As a supplementation, we manually checked the citations of the relevant original and reviewed articles for possible studies of interest.

2.2. Study Selection. The PICOS criteria were used for study inclusion.

P (patients) denotes adult patient with NSCLC receiving ICIs, including PD-1/PD-L1 inhibitors, CTLA4 inhibitors, or their combination. No restriction was applied to the pathological types of NSCLC (squamous cell carcinoma, adenocarcinoma, or other types of NSCLC).

I (exposure) denotes patients with concomitant use of statins as evidenced by the medical charts or other medical records with no restrictions to the category, dosages, or durations of statin use.

C (control) denotes patients without concomitant use of statins which were also evidenced by the medical charts or other medical records.

O (outcomes) denotes progression-free survival (PFS) and/or overall survival (OS) between users and nonusers of statins, reported as relative risk. We defined OS as the time elapsed from treatment and to the date of death from any cause and PFS as the interval between initiation of the treatment and the first recurrence or progression event.

S (study design) denotes cohort studies published as full-length articles.

Reviews, preclinical studies, studies with non-NSCLC patients, studies with no treatment of ICIs, or studies that did not report the outcomes of interest were removed. Moreover, grey literature studies such as conferences, abstracts, or unpublished data were also not considered. These materials were generally not peer-reviewed, and inclusion of these data into the meta-analysis may confound the results.

2.3. Data Collection and Quality Assessment. Two independent authors conducted literature search and analysis, data collection, and study quality assessment separately. If discrepancies were encountered, the corresponding author joined the discussion for final judgement. Data of study information, patient demographic factors, types of ICIs, definition of concurrent statin application, outcomes reported, and analytic methods were collected. Study quality assessment was achieved via the Newcastle–Ottawa Scale [32], with scoring regarding the criteria for participant selection, comparability of the groups, and the validity of the outcomes. The scale ranged between 1 and 9 stars, with the larger number of stars presenting higher study quality.

2.4. Statistical Analyses. The main objective was to determine the influence of concomitant statin on survival of patients with NSCLC on treatment of ICIs, which was presented with hazard ratios (HRs) as well as their confidence intervals (CIs). Using the 95% CIs or P values, data of RR and the standard errors (SEs) could be calculated, and a subsequent logarithmical transformation was conducted to keep stabilized variance and normalized distribution [31]. Between-study heterogeneity was estimated with Cochrane’s Q test and the P statistic [33], with P > 50% reflecting the significant heterogeneity. A random-effect model was applied to combine the results by incorporating the influence of heterogeneity [31]. We observed the influence of each study on the overall results by performing sensitivity analyses, which omitted one study at a time [34]. Subgroup analyses were also performed to explore the different analytic model of the study on the outcome. By construction of the funnel plots, the publication bias was estimated based on the visual judgement of the symmetry of the plots,
supplemented with Egger’s regression asymmetry test [35].
The RevMan (Version 5.1; Cochrane Collaboration, Oxford, UK) software package was applied for these analyses.

3. Results

3.1. Studies Obtained. Figure 1 shows the process of literature analysis. In short, the initial search of the databases retrieved 722 studies after removing the duplicated records. Then, an additional of 694 articles were excluded since the contents of titles and abstracts indicated they were not relevant to the meta-analysis, which made a total of 28 studies for a full-text review. Finally, after excluding 20 studies through full-text review, eight cohort studies [15, 23–29] were included. Reasons for removing the 19 studies are also presented in Figure 1.

3.2. Characteristics of the Included Studies. As shown in Table 1, eight cohort studies [15, 23–29] including 2382 patients with NSCLC who were receiving ICIs were included. These studies were performed within 2019 to 2022 and located in Japan [23, 27, 29], Czech [24], Italy [25, 26, 28], and France [15], respectively. Most of the studies were retrospective except one study [23], which was prospective. Seven of the studies [23–29] included advanced NSCLC patients treated with PD-1/PD-L1 inhibitors, such as pembrolizumab, nivolumab, or atezolizumab etc., while the other study included patients treated with PD-1/PD-L1 inhibitors, CTLA4 inhibitors, or their combination [15]. The mean ages of the patients were 65 to 71 years. Concomitant use of statin was validated by medical records or database in all studies. A total of 513 (21.5%) patients were with concomitant use of statin. Four studies reported the association between concomitant statin and survival outcomes with univariate analyses [15, 23, 26, 28], while the other four studies reported with multivariate analyses [24, 25, 27, 29]. Variables including demographic features, cancer characteristics, and smoking history were adjusted in the multivariate models. The NOS of the included studies were 6 to 8 stars, suggesting generally good study quality (Table 2).

3.3. Concomitant Statin and PFS in NSCLC Patients Taking ICIs. Influence of concomitant statin on PFS in NSCLC patients treated with ICIs was reported in all of the eight studies. Pooled results showed that concomitant use of statin was not associated with a significantly improved PFS (HR: 0.86, 95% CI: 0.70 to 1.07, \( P = 0.17 \); Figure 2(a)) with significant heterogeneity (\( P \) for Cochrane’s Q test = 0.009, \( I^2 = 62\% \)). Sensitivity analysis by excluding one study at a time showed consistent result (HR: 0.81 to 0.90, \( P \) all > 0.05). Specifically, sensitivity analysis limited to studies of patients taking PD-1/PD-L1 only showed consistent result (HR: 0.83, 95% CI: 0.66 to 1.03, \( P = 0.10 \), \( I^2 = 64\% \)). Subgroup analyses also showed consistent results in univariate (HR: 0.86, 95% CI: 0.67 to 1.11, \( P = 0.24 \), \( I^2 = 66\% \)) and multivariate studies (HR: 0.85, 95% CI: 0.55 to 1.33, \( P = 0.49 \), \( I^2 = 69\% \); \( P \) for subgroup difference = 0.97, Figure 2(b)).
| Study                  | Country | Design | Patient characteristics | Sample size | Mean age (years) | Male (%) | ICIs used | Definition of statin use | Number of statin users | Outcomes reported | Variables adjusted                               |
|-----------------------|---------|--------|-------------------------|-------------|------------------|----------|-----------|--------------------------|-----------------------|-------------------|-------------------------------------------------|
| Omori et al. [23]     | Japan   | P      | Advanced NSCLC          | 67          | 67               | 69       | Nivolumab | Concomitant statin evidenced by the medical records | 10                    | PFS and OS | None                                            |
| Svaton et al. [24]    | Czech   | R      | Advanced NSCLC          | 224         | 67               | 59       | Nivolumab | Concomitant statin evidenced by the medical records | 31                    | PFS and OS | Age, sex, PS, smoking, histologic type, cancer stage, and concurrent medications |
| Rossi et al. [28]     | Italy   | R      | Metastatic NSCLC        | 122         | 71               | 65       | Nivolumab, pembrolizumab, or atezolizumab | Concomitant statin evidenced by the medical records | 70                    | PFS and OS | None                                            |
| Cantini et al. [25]   | Italy   | R      | Advanced NSCLC          | 179         | 67               | 72       | Nivolumab or pembrolizumab | Concomitant statin evidenced by the medical records | 39                    | PFS and OS | Age, sex, smoking, PS, and histologic type        |
| Kostine et al. [15]   | France  | R      | Advanced NSCLC          | 150         | 65               | 70       | PD-1/PD-L1 and/or CTLA4 inhibitors | Concomitant statin evidenced by the medical records | 32                    | PFS and OS | None                                            |
| Cortellini et al. [26]| Italy   | R      | Metastatic NSCLC        | 950         | 70               | 66       | Pembrolizumab | Concomitant statin evidenced by the medical records | 252                   | PFS and OS | None                                            |
| Miura et al. [27]     | Japan   | R      | Metastatic NSCLC        | 300         | 65               | 75       | Nivolumab or pembrolizumab | Concomitant statin evidenced by the medical records | 26                    | PFS and OS | Age, sex, PS, histologic type, previous therapy, and concurrent medications |
| Takada et al. [29]    | Japan   | R      | Advanced or recurrent NSCLC | 390       | 67               | 79       | Nivolumab or pembrolizumab | Concomitant statin evidenced by the medical records | 53                    | PFS and OS | Age, sex, PS, cancer stage, histologic type, mutational status, and BMI |

ICIs, immune checkpoint inhibitors; P, prospective; R, retrospective; NSCLC, nonsmall cell lung cancer; PD-1/PD-L1, programmed death-1/ligand-1; CTLA4, cytotoxic T-lymphocyte associated protein 4; PFS, progression-free survival; OS, overall survival; PS, performance status; BMI, body mass index.
Table 2: Details of study quality evaluation via the Newcastle–Ottawa Scale.

| Study            | Representativeness of the exposed cohort | Selection of the nonexposed cohort | Ascertainment of exposure | Outcome not present at baseline | Control for age | Control for other confounding factors | Assessment of outcome | Enough long follow-up duration | Adequacy of follow-up of cohorts | Total |
|------------------|------------------------------------------|------------------------------------|----------------------------|---------------------------------|-----------------|---------------------------------------|----------------------|-------------------------------|---------------------------------|-------|
| Omori et al.     | 1                                        | 1                                  | 1                          | 1                               | 0               | 0                                     | 1                    | 1                             | 0                               | 7     |
| Svaton et al.    | 0                                        | 1                                  | 1                          | 1                               | 1               | 1                                     | 1                    | 1                             | 1                               | 8     |
| Rossi et al.     | 0                                        | 1                                  | 1                          | 1                               | 0               | 0                                     | 1                    | 1                             | 1                               | 6     |
| Cantini et al.   | 0                                        | 1                                  | 1                          | 1                               | 1               | 1                                     | 1                    | 1                             | 1                               | 8     |
| Kostine et al.   | 0                                        | 1                                  | 1                          | 1                               | 0               | 0                                     | 1                    | 1                             | 1                               | 6     |
| Cortellini et al.| 0                                        | 1                                  | 1                          | 1                               | 0               | 0                                     | 1                    | 1                             | 1                               | 6     |
| Miura et al.     | 0                                        | 1                                  | 1                          | 1                               | 1               | 1                                     | 1                    | 1                             | 1                               | 8     |
| Takada et al.    | 0                                        | 1                                  | 1                          | 1                               | 1               | 1                                     | 1                    | 1                             | 1                               | 8     |
3.4. Concomitant Statin and OS in NSCLC Patients Taking ICIs. Influence of concomitant statin on OS in NSCLC patients treated with ICIs was also reported in all of the eight studies. Pooled results showed that concomitant use of statin was not associated with a significantly improved OS (HR: 0.86, 95% CI: 0.74 to 1.01, \( P = 0.07 \); Figure 3(a)) with mild heterogeneity (\( P \) for Cochrane’s \( Q \) test = 0.20, \( I^2 \) = 29%). Sensitivity analysis by excluding one study at a time showed consistent results (HR: 0.79 to 0.91, \( P \) all >0.05). Specifically, sensitivity analysis limited to studies of patients taking PD-1/PD-L1 only showed consistent results (HR: 0.84, 95% CI: 0.71 to 1.01, \( P = 0.07 \), \( I^2 \) = 37%). Subgroup analyses also showed consistent results in univariate (HR: 0.90, 95% CI: 0.74 to 1.09, \( P = 0.27 \), \( I^2 \) = 47%) and multivariate studies (HR: 0.77, 95% CI: 0.57 to 1.03, \( P = 0.07 \), \( I^2 \) = 0%; \( P \) for subgroup difference = 0.38, Figure 3(b)).

3.5. Publication Bias. Figures 4(a) and 4(b) display the funnel plots for the outcomes of PFS and OS. Visual inspection revealed symmetry of the plots, reflecting a low risk of publication biases. Egger’s regression tests also indicated low risk of publication biases (\( P = 0.512 \) and 0.693, respectively).

4. Discussion

In this meta-analysis, we pooled the results of eight cohort studies and showed that concomitant use of statins in
NSCLC patients receiving ICIs treatment was not associated with significantly improved survival outcomes, including PFS and OS. Further sensitivity analyses by excluding one study at a time did not significantly affect the results. Moreover, sensitivity analysis limited to studies including NSCLC patients receiving PD-1/PD-1L inhibitors also showed similar results. Finally, subgroup analyses showed that concomitant use of statins in NSCLC patients was not associated with a significantly improved PFS or OS in univariate or multivariate studies. Taken together, current evidence primarily based on retrospective studies in NSCLC patients taking PD-1/PD-1L inhibitors did not show that concurrent use of statins was associated with a significantly improved survival in these patients. Although these results should be further confirmed in large-scale prospective studies, these results did not support the previous hypothesis that concomitant statins may improve the anticancer efficacy of ICIs in patients with NSCLC.

To the best of our knowledge, this is the first meta-analysis which summarized the current evidence regarding the influence of concomitant statins in patients with NSCLC receiving ICIs treatment. During the preparation of the manuscript, a meta-analysis was published to evaluate the possible influence of concomitant medications, including statins, on the survival in patients with advanced cancer who were treated with ICIs [36]. However, only five studies were included in their analysis, and studies including various malignancies were included [36]. Although it was shown that concomitant statin may be associated with improved PFS and OS in overall meta-analyses including patients with...

| Study or Subgroup | log [Hazard Ratio] | SE | Weight (%) | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|-------------------|----|------------|---------------------------------|---------------------------------|
| Omori et al 2019  | -0.2107           | 0.15891 | 16.5       | 0.81 [0.59, 1.11]               |                                 |
| Svaton et al 2020 | -0.2744           | 0.33849 | 5.0        | 0.76 [0.39, 1.48]               |                                 |
| Rossi et al 2021  | -0.3011           | 0.13031 | 21.0       | 0.74 [0.57, 0.96]               |                                 |
| Cantini et al 2021| -0.3857           | 0.29756 | 6.3        | 0.68 [0.38, 1.22]               |                                 |
| Kostine et al 2021| 0.01              | 0.22819 | 9.8        | 1.01 [0.65, 1.58]               |                                 |
| Cortellini et al 2021 | 0.0583           | 0.09757 | 27.7       | 1.06 [0.88, 1.28]               |                                 |
| Miura et al 2021  | 0.174             | 0.3087  | 5.9        | 1.19 [0.65, 2.18]               |                                 |
| Takada et al 2022 | -0.4943           | 0.26568 | 7.7        | 0.61 [0.36, 1.03]               |                                 |
| **Total (95% CI)**| **100.0**         |        |            | **0.86 [0.74, 1.01]**           |                                 |

**Figure 3:** Forest plots for the meta-analysis of the influence of concomitant statin on OS of NSCLC patients receiving ICIs. (a) Forest plots for the overall meta-analysis; (b) subgroup analysis in univariate and multivariate studies.
advanced cancers, the authors were not able to determine whether the association remained in patients with NSCLC [36]. This is important because it has been acknowledged that patients with different malignancies may respond differently to immunotherapies [37]. Our meta-analysis, on the other hand, included eight studies of patients with NSCLC only and showed that concomitant use of statins in NSCLC patients was not associated with a significantly improved PFS or OS. The robustness of the finding was validated by sensitivity analyses and subgroup analyses in univariate and multivariate studies. Results of the meta-analysis were also not consistent with previous findings in preclinical studies which showed synergistic anticancer actions of statins on the anticancer efficacy of ICIs [20]. Previous experimental studies showed that statins may synergize with PD-1 inhibitors via attenuating the expression of PD-1 and CTLA-4 in T cells and increasing antigen occupation in dendritic cells [38, 39]. However, these benefits of statins were primarily observed in cultured cancer cell lines or murine models of cancer, which may not be the case in patients with advanced NSCLC, possibly due to the difference in dosages of statins and the influences of comorbidities and concurrent medications. Future studies are warranted to clarify the mechanisms underlying the inconsistency between related preclinical and observational studies.

Two early meta-analyses have suggested the possible benefit of statin use on survival of patients with lung cancer [18, 19]. However, it should be clarified that none of the studies which contributed to these meta-analyses include patients that received ICIs. Therefore, the previous suggested survival benefit of statins for lung cancer patients may not exist for NSCLC patients receiving ICIs. In fact, a recent retrospective cohort study including 2757 patients with advanced cancer who were treated with ICIs showed that concurrent statin therapy in these patients was independently associated with higher risk of skeletal myopathies [40]. The possible influences of concurrent statins on the prognosis and the possible risk of adverse events in NSCLC patients who were treated with ICIs should be further evaluated.

This meta-analysis also has some limitations. Firstly, most of the studies were retrospective and of limited sample sizes, results of which may be affected by possible recall and selection biases. Accordingly, large-scale prospective cohort studies are needed to validate the findings. Secondly, we could not determine whether difference in the individual category of statins may affect the association of interest since related data were rarely reported among the included studies. Studies are warranted in the future for investigation. Besides, most of the included patients received PD-1/PD-L1 inhibitors rather than CTLA-4 inhibitors. The possible influence of concomitant statin use on survival in NSCLC patients receiving CTLA-4 inhibitors is still to be determined. Finally, although subgroup analysis of multivariate analysis showed consistent results, it remained unknown whether age, sex, ethnicity, comorbidities, and other concurrent medications may significantly affect the association between concomitant statin and survival of these patients, which may be the source of heterogeneity among the included studies. Meta-analysis based on individual-patient data should be performed for further evaluation.

To sum up, current evidence from observational studies did not show that concurrent use of statins was associated with a significantly improved survival in NSCLC patients receiving ICIs. Although these results should be further confirmed in large-scale prospective studies, in view of the possible increased risk of adverse events such as skeletal myopathies, concomitant use of statins in NSCLC patients receiving ICIs should be cautious.

Data Availability

The data adopted in this meta-analysis are available from the corresponding author on reasonable request.

Ethical Approval

An ethics statement is not applicable because this study is based exclusively on the published literature.
Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Lei Zhang and Xiaoyan Chen designed the study. Lei Zhang and Hong Wang performed database search, data extraction, and study quality evaluation. Lei Zhang, Jizheng Tian, and Lili Su performed statistical analyses and interpreted the results. Lei Zhang drafted the manuscript. Xiaoyan Chen revised the manuscript. All authors approved the submission of the manuscript.

Supplementary Materials

Database Search Strategy. (“statin” OR “3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor” OR “CS-514” OR “statin” OR “simvastatin” OR “atorvastatin” OR “fluvastatin” OR “lovastatin” OR “rosuvastatin” OR “pravastatin” OR “pitavastatin”) AND “lung cancer” AND (“survival” OR “mortality” OR “prognosis” OR “death” OR “recurrence” OR “collapse”). (Supplementary Materials)

References

[1] G. Pasello, A. Pavan, I. Attili et al., “Real world data in the era of immune checkpoint inhibitors (ICIs): increasing evidence and future applications in lung cancer,” Cancer Treatment Reviews, vol. 87, Article ID 102031, 2020.
[2] H. Akhbariyooyo, Y. Azizpour, M. F. Esfahani et al., “Immune checkpoint inhibition for the treatment of cancers: an update and critical review of ongoing clinical trials,” Clinical Immunology, vol. 232, Article ID 108873, 2021.
[3] T. Kinoshita, H. Terai, and T. Yaguchi, “Clinical efficacy and future prospects of immunotherapy in lung cancer,” Life (Basel, Switzerland), vol. 11, no. 10, 2021.
[4] A. Ribas and J. D. Wolchok, “Cancer immunotherapy using checkpoint blockade,” Science, vol. 359, no. 6382, pp. 1350–1355, 2018.
[5] K. Suresh, J. Naidoo, C. T. Lin, and S. Danoff, “Immune checkpoint immunotherapy for non-small cell lung cancer,” Chest, vol. 154, no. 6, pp. 1416–1423, 2018.
[6] C. Cao, A. Le, M. Bott et al., “Meta-analysis of neoadjuvant immunotherapy for patients with resectable non-small cell lung cancer,” Current Oncology, vol. 28, no. 6, pp. 4686–4701, 2021.
[7] A. Juarez-Garcia, R. Sharma, M. Hunger, S. Kayaniyil, J. R. Penrod, and C. Chouaid, “Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer patients: a systematic literature review,” Lung Cancer, vol. 166, pp. 205–220, 2022.
[8] N. Shukla and N. Hanna, “Neoadjuvant and adjuvant immunotherapy in early-stage non-small cell lung cancer,” Lung Cancer: Targets and Therapy, vol. 12, pp. 51–60, 2021.
[9] F. Alex and A. Alfredo, “Promising predictors of checkpoint inhibitor response in NSCLC,” Expert Review of Anticancer Therapy, vol. 20, no. 11, pp. 931–937, 2020.
[10] S. Rossi, A. Castello, L. Toschi, and E. Lopci, “Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity,” Immunotherapy, vol. 10, no. 9, pp. 797–805, 2018.
[11] G. Huo, W. Liu, and P. Chen, “Inhibitors of PD-1 in non-small cell lung cancer: a meta-analysis of clinical and molecular features,” Frontiers in Immunology, vol. 13, Article ID 875093, 2022.
[12] S. Buti, M. Bersanelli, F. Perrone et al., “Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index,” European Journal of Cancer, vol. 142, pp. 18–28, 2021.
[13] L. Horvath, B. Thienpont, L. Zhao, D. Wolf, and A. Pircher, “Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)-novel approaches and future outlook,” Molecular Cancer, vol. 19, no. 1, p. 141, 2020.
[14] A. Oesterle, U. Laufs, and J. K. Liao, “Pleiotropic effects of statins on the cardiovascular system,” Circulation Research, vol. 120, no. 1, pp. 229–243, 2017.
[15] M. Kostine, E. Mauric, A. Tison et al., “Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events,” European Journal of Cancer, vol. 157, pp. 474–484, 2021.
[16] J. Longo, J. E. van Leeuwen, M. Elbaz, E. Branchard, and L. Z. Penn, “Statins as anticancer agents in the era of precision medicine,” Clinical Cancer Research, vol. 26, no. 22, pp. 5791–5800, 2020.
[17] A. Markowska, M. Antosczak, J. Markowska, and A. Huczyński, “Statins: HMG-CoA reductase inhibitors as potential anticancer agents against malignant neoplasms in women,” Pharmaceuticals, vol. 13, no. 12, 2020.
[18] D. K. Xia, Z. G. Hu, Y. F. Tian, and F. J. Zeng, “Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials,” Drug Design, Development and Therapy, vol. 13, pp. 405–422, 2019.
[19] Y. Chen, X. Li, R. Zhang, Y. Xia, Z. Shao, and Z. Mei, “Effects of statin exposure and lung cancer survival: a meta-analysis of observational studies,” Pharmacological Research, vol. 141, pp. 357–365, 2019.
[20] M. Matsushita and M. Kawaguchi, “Immunomodulatory effects of drugs for effective cancer immunotherapy,” Journal of oncology, vol. 2018, Article ID 8653489, 7 pages, 2018.
[21] T. H. Shwe, P. Pothacharoen, T. Phitak, B. Wudtiwai, and P. Kongtawelet, “Atorvastatin attenuates programmed death ligand-1 (PD-L1) induction in human hepatocellular carcinoma cells,” International Journal of Molecular Sciences, vol. 22, no. 16, 2021.
[22] B. Halder, S. Das Gupta, and A. Gomes, “Black tea polyphenols induce human leukemic cell cycle arrest by inhibiting akt signaling,” FEBS Journal, vol. 279, no. 16, pp. 2876–2891, 2012.
[23] M. Omori, Y. Okuma, T. Hakoizaki, and Y. Hosomi, “Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: an observational study,” Molecular and clinical oncology, vol. 10, no. 1, pp. 137–143, 2019.
[24] M. Svaton, M. Zemanova, P. Zemanova et al., “Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer,” Anticancer Research, vol. 40, no. 4, pp. 2209–2217, 2020.
[25] L. Cantini, F. Pecci, D. P. Hurkmans et al., “High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced
non-small cell lung cancer patients,” *European Journal of Cancer*, vol. 144, pp. 41–48, 2021.

[26] A. Cortellini, M. Di Maio, O. Nigro et al., ”Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy,” *Journal for Immunotherapy of Cancer*, vol. 9, no. 4, 2021.

[27] K. Miura, Y. Sano, S. Niho et al., ”Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study,” *Thoracic Cancer*, vol. 12, no. 13, pp. 1983–1994, 2021.

[28] A. Rossi, M. Filetti, B. Taurelli Salimbeni et al., ”Statins and immunotherapy: togetherness makes strength the potential effect of statins on immunotherapy for NSCLC,” *Cancer reports (Hoboken, N.J.)*, vol. 4, no. 4, Article ID e1368, 2021.

[29] K. Takada, M. Shimokawa, S. Takamori et al., ”A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study,” *BMC Cancer*, vol. 22, no. 1, p. 503, 2022.

[30] D. F. Stroup, J. A. Berlin, S. C. Morton et al., ”Meta-analysis of observational studies in epidemiology: a proposal for reporting,” *JAMA*, vol. 283, no. 15, pp. 2008–2012, 2000.

[31] J. Higgins and S. Green, ”Cochrane handbook for systematic reviews of interventions version 5.1.0. The cochrane collaboration,” 2011, https://www.cochranehandbook.org.

[32] G. A. Wells, B. Shea, D. O’Connell et al., ”The newcastle-ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses,” 2010, https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

[33] J. P. Higgins and S. G. Thompson, ”Quantifying heterogeneity in a meta-analysis,” *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.

[34] N. A. Patsopoulos, E. Evangelou, and J. P. Ioannidis, ”Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation,” *International Journal of Epidemiology*, vol. 37, no. 5, pp. 1148–1157, 2008.

[35] M. Egger, G. Smith, M. Schneider, and C. Minder, ”Bias in meta-analysis detected by a simple, graphical test,” *BMJ*, vol. 315, no. 709, pp. 629–634, 1997.

[36] Y. Zhang, H. Chen, S. Chen, Z. Li, J. Chen, and W. Li, ”The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis,” *OncoImmunology*, vol. 10, no. 1, Article ID 1957605, 2021.

[37] S. Das, K. Camphausen, and U. Shankavaram, ”Cancer-specific immune prognostic signature in solid tumors and its relation to immune checkpoint therapies,” *Cancers*, vol. 12, no. 9, 2020.

[38] I. Okoye, A. Namdar, L. Xu, N. Crux, and S. Elahi, ”Atorvastatin downregulates co-inhibitory receptor expression by targeting ras-activated mTOR signalling,” *Oncotarget*, vol. 8, no. 58, pp. 98215–98232, 2017.

[39] Y. Xia, Y. Xie, Z. Yu et al., ”The mevalonate pathway is a druggable target for vaccine adjuvant discovery,” *Cell*, vol. 175, no. 4, pp. 1059–1073, 2018.

[40] Z. D. Drobní, S. P. Murphy, R. M. Alvi et al., ”Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors,” *Immunotherapy Advances*, vol. 1, no. 1, Article ID itab014, 2021.